Product Launch

Las Vegas – October 02, 2026 -- Rareview Capital LLC has launched the Rareview Bloomberg Commodity Index ETF, trading under the symbol BCOM, offering passive exposure to the Bloomberg Commodity Index Total Return.

Fund tracks 24 futures contracts across 22 commodities as of April 30, 2026

The ETF is weighted two-thirds by trading volume or liquidity and one-third by world production or global economic significance. Weight caps limit any single commodity to 15% and any sector to 33%, capping concentration risk across energy, metals, agriculture and livestock.

South San Francisco, Calif. – October 02, 2026 -- AKASA has launched an autonomous AI platform for inpatient medical coding and clinical documentation integrity (CDI), expanding beyond its existing prebill review tools after inpatient volume processed by the company grew nearly 6x over the past year.

AKASA's health system customers now cover 10% of U.S. inpatient discharges

The company's customer base collectively represents more than $180 billion in aggregate net patient revenue and roughly 10% of all U.S. inpatient discharges. The growth has been driven by adoption of AKASA's existing AI-powered prebill review products, which the company says created the volume and performance data needed to move into fully autonomous coding.

Nottingham, England – October 02, 2026 -- Quotient Sciences and Copenhagen-based Acesion Pharma have launched a collaboration to apply AI-enhanced formulation development to Acesion's early-stage pipeline of small molecules targeting atrial fibrillation, a condition affecting an estimated 50-60 million people globally.

AI tool uses Bayesian optimization to screen drug formulations for clinical success

The collaboration deploys Quotient Sciences' new AI-enhanced formulation development solution within its Translational Pharmaceutics platform, applying active machine learning with Bayesian optimization to identify and prioritize drug products most likely to succeed in clinical testing. The approach is designed to compress early clinical decision-making timelines for sponsors developing new treatments.

Hong Kong – – October 02, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) presented preclinical data showing its ASC36_35FDC injectable combination drove a 24.8% body-weight reduction in a diet-induced obesity rat model on Day 14, outperforming two competitor co-formulations tested under identical dosing conditions.

The data were unveiled in a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, held September 28–October 2, 2026, in Milan, Italy.

Jeddah – October 02, 2026 -- The Mysk Al Wadi Jeddah Hotel, the first Mysk-branded luxury property in Saudi Arabia, will open in September 2026 after builders treated over 2,000 cubic meters of concrete with crystalline waterproofing admixture to counter high groundwater and chloride exposure at the Red Sea construction site.

General contractor specified PENETRON ADMIX for below-grade structures exposed to groundwater

Faraj Abdulkarim Est, the project's general contractor, required a waterproofing solution for below-grade concrete after excavation depths revealed elevated groundwater levels at the site in Jeddah's Obhur district, near the Jeddah Corniche. Sam Annous, Managing Director of Penetron Saudi Arabia, said the hotel's proximity to the Red Sea made resilience against chloride-rich conditions a parallel priority alongside groundwater control.

Valby – October 02, 2026 -- H. Lundbeck A/S will present late-breaking Phase III data on its multiple system atrophy (MSA) drug candidate amlenetug alongside new Parkinson's disease pipeline results at the International Congress of Parkinson's Disease and Movement Disorders (MDS) 2026 in Seoul, South Korea, running October 4-8.

MASCOT trial enrolled 401 participants across a global Phase III program

The late-breaking oral presentation will detail baseline characteristics of participants in MASCOT (NCT06706622), Lundbeck's ongoing Phase III trial of amlenetug in MSA. The trial enrolled 401 participants with clinically probable or established MSA, covering both MSA-C and MSA-P subtypes, across sites in North America, Europe, Asia and Australia. The double-blind treatment period runs 72 weeks, comparing high- and low-dose amlenetug against placebo, with results expected in Q3 2027.

Seoul – October 02, 2026 -- AUTOCRYPT has established a Public Key Infrastructure (PKI) system for Plug&Charge (PnC) services in South Korea, validated across electric vehicles from six global automotive brands.

Six automakers validate shared authentication framework

The PKI infrastructure was tested on vehicles from Hyundai Motor, Kia, KG Mobility, BMW, Mercedes-Benz and Tesla, enabling these brands to connect to charging point operators (CPOs) through a single authentication system rather than separate proprietary frameworks.

Singapore – October 02, 2026 -- AhaSlides has won the 2026 Training Magazine Network Choice Award in the Gamification & Game-Based Learning category, a prize decided entirely by votes from working L&D professionals rather than editorial judges.

Voting pool of 2,207 trainers cast 11,692 votes across 296 companies

The Choice Awards, run by Training Magazine Network's 100,000+ member base, collected ballots between April 28 and June 30, 2026, spanning seven categories. Training magazine Editor/Publisher Lorri Freifeld announced the results on September 29, 2026.

Beijing – October 02, 2026 -- iQIYI's AIGC film series "The Ferry Man" has generated cumulative revenue-sharing earnings exceeding RMB 8 million (US$1.2 million) as of September 23, validating artificial intelligence as a financially viable film production model. The milestone arrives as the third installment, "The Ferry Man: The Dream of the Princess", debuts October 1 on iQIYI and iQIYI International.

Production costs recovered within first week of release

The series, produced jointly by iQIYI and GHY Culture & Media, recovered its full production costs within seven days of launch and crossed the RMB 8 million revenue-sharing threshold within its first month, according to the company. The first two titles, "Butterfly Dream" and "The Dream of the Celestial Maiden", released simultaneously on August 22.

San Francisco -- October 02, 2026 -- MontoHealth is developing an AI-driven action layer designed to execute routine healthcare tasks—not just discuss them—across existing hospital and clinic software systems.

MontoHealth targets the gap between digitized records and automated work

Despite two decades of healthcare digitization, tasks such as rescheduling an appointment, routing a prescription refill, coordinating a referral or resolving an insurance query still require manual phone calls and handoffs across disconnected systems. Healthcare organizations typically operate EHRs, scheduling platforms, billing systems and patient portals as separate applications, each governed by distinct privacy and security controls. MontoHealth argues that digitizing a workflow has not equated to automating it, leaving staff to perform the connective work between systems.